Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.

Madan RA, Arlen PM, Gulley JL.

Expert Opin Biol Ther. 2007 Apr;7(4):543-54. Review.

PMID:
17373905
2.

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.

Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, Higgins JP, Hodge JW, Steinberg SM, Kotz H, Dahut WL, Schlom J.

Clin Cancer Res. 2008 May 15;14(10):3060-9. doi: 10.1158/1078-0432.CCR-08-0126.

3.

Vaccine therapy of established tumors in the absence of autoimmunity.

Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.

Clin Cancer Res. 2003 May;9(5):1837-49.

4.

Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC).

Vasir B, Zarwan C, Ahmad R, Crawford KD, Rajabi H, Matsuoka K, Rosenblatt J, Wu Z, Mills H, Kufe D, Avigan D.

J Immunother. 2012 Sep;35(7):555-69. doi: 10.1097/CJI.0b013e31826a73de.

5.

Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer.

Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, Kim DW, Marshall J.

J Transl Med. 2007 Nov 26;5:60.

6.

Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.

Grosenbach DW, Barrientos JC, Schlom J, Hodge JW.

Cancer Res. 2001 Jun 1;61(11):4497-505.

7.

Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.

Tsang KY, Palena C, Yokokawa J, Arlen PM, Gulley JL, Mazzara GP, Gritz L, Yafal AG, Ogueta S, Greenhalgh P, Manson K, Panicali D, Schlom J.

Clin Cancer Res. 2005 Feb 15;11(4):1597-607.

9.

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.

Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J.

J Clin Oncol. 2005 Feb 1;23(4):720-31. Epub 2004 Dec 21.

10.

Development of the PANVAC-VF vaccine for pancreatic cancer.

Petrulio CA, Kaufman HL.

Expert Rev Vaccines. 2006 Feb;5(1):9-19. Review.

PMID:
16451103
11.
12.

Carcinoembryonic antigen-based vaccines.

Marshall J.

Semin Oncol. 2003 Jun;30(3 Suppl 8):30-6. Review.

PMID:
12881810
13.

A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.

Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bulusu A, Annechiarico RP, Chadaram V, Clay TM, Lyerly HK.

Ann Surg. 2013 Dec;258(6):879-86. doi: 10.1097/SLA.0b013e318292919e.

14.
15.

A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.

Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL.

Clin Cancer Res. 2011 Nov 15;17(22):7164-73. doi: 10.1158/1078-0432.CCR-11-0649. Epub 2011 Nov 8.

16.

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.

Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J, Hamilton JM.

Cancer Immunol Immunother. 2000 Dec;49(10):517-29.

PMID:
11129322
Items per page

Supplemental Content

Write to the Help Desk